Most drug programs do not fail just because the science was not right. Many stop because people need to do a study again, the data does not hold up when someone looks at it, or the partner doing the work cannot answer a simple question fast. The preclinical work is the place where you can find these problems early. If not, fixing them can cost a lot more money down the road. Picking the right research partner is a choice that shapes every step after this.
Why the Choice of Partner Matters So Much
Preclinical research comes between a new drug and the very first tests in people. It finds out how a molecule moves through the body, gets taken in, travels around, is changed, and leaves the body. It checks if it works the way you think it should in a test for the disease. It also asks if it is safe enough to give to people.
For many small and mid-sized biotech companies, working with a preclinical UK CRO lets them get the help of expert scientists. They also get to use tried-and-tested tests for new drugs, without having to make a lab on their own.
ScienceDirect’s overview of preclinical studies is also a good way to look back at how these steps work in the bigger plan of drug development.
What a Preclinical Package Usually Includes
Though all programs may not be identical, most IND/CTA-enabling programs will include a combination of the following:
• In vitro ADME: This tests for stability within the body, protein binding in blood, cellular permeability, and inhibition of certain liver enzymes.
• Pharmacokinetics (PK): how the levels of the drug within the body increase and decrease once ingested, and typically assessed in multiple species.
• Bioanalysis: using well-established methods, mainly LC-MS/MS, for measuring the drug and its metabolites, which is helpful for obtaining accurate measurements.
• Efficacy models: disease models that demonstrate the efficacy of the drug.
• Safety and toxicology: studies used for dose range and guidance purposes can be useful for determining a safe starting dose.
Why Many Sponsors Look to the UK
The UK has been strong in drug discovery for a long time. There are many universities, hospitals, and life-science companies close to each other. The UK regulator, called MHRA, runs a monitoring program for GLP. The UK also works with the OECD system that lets countries use each other’s data.
This means that if you run GLP studies in the UK that meet the rules, it helps you send your results to other OECD countries. You can read more about how this system works on the OECD’s page on Good Laboratory Practice and compliance monitoring.
Seven Questions to Ask Before You Sign
- Who designs the study? A good partner will question how you plan to run the study and offer ideas to make it better, instead of just giving a price.
- What is their regulatory experience? Ask who has used their data, like the MHRA, FDA, or EMA.
- Which studies are GLP and which aren’t? You often do not need GLP for early screening. But, when it comes to important safety work, it is usually done with GLP.
- How do they handle data? Check if they use audit trails, controlled systems and if you can see clear raw-data.
- How fast is turnaround? When you do early PK, you can save weeks. This can help to move your whole programme ahead.
- Who will you actually talk to? Getting to talk right to the study director is better than having to speak with a line of managers.
- Can they grow with you? A partner who takes care of discovery screening and the work that comes after saves you from a tough handover.
Red Flags Worth Noticing Early
Be careful if a provider cannot tell you how a study connects to your regulatory goal. Watch out if the timelines are unclear or the provider promises good results before looking at your product. A very low price might mean they skip steps, like doing fewer repeats or controls. A short call with the science lead often tells you more than looking at a long sales brochure. Ask them to show an example report from another study like yours, with private details taken out. This way, you can see for yourself if their reports are good.
Conclusion
The right preclinical partner does more than do tests. They help you ask good questions. They help you not do studies again. They help you go into meetings with data you feel sure about. Take the time to look at their science. Check how their systems work. Make sure their people are right for you before you go forward. Doing this costs much less than fixing bad data after.
FAQs
What does “IND-enabling” mean?
It says what studies a regulator wants to have before the drug goes into tests with people.
Do all preclinical studies need to be GLP?
No, the work for finding and early checking is usually not GLP. Key safety studies need to be GLP.
How long does a preclinical package take?
It can be different for each program, but most take one year or two years.






